The production of bulk organic chemicals has a strong impact on our daily life.In this review,an overview of important industrial processes using homogeneous catalysts is given.Using specific carbonylation and hydroge...The production of bulk organic chemicals has a strong impact on our daily life.In this review,an overview of important industrial processes using homogeneous catalysts is given.Using specific carbonylation and hydrogenation case studies,we want to show how basic research can contribute to the development of such processes and what challenges exist in this area of academic research.展开更多
Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)remains a significant health problem with an increase in the incidence and a five-year survival rate of only 10%[1].The Phosphoinositide 3-kinase-protein kinase-B-mech...Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)remains a significant health problem with an increase in the incidence and a five-year survival rate of only 10%[1].The Phosphoinositide 3-kinase-protein kinase-B-mechanistic target of rapamycin(PI3K-AKT-mTOR)pathway is a driver pathway in PDAC and an important therapeutic target[2].We[3]and others[4–6]have demonstrated that the mTOR kinase is a therapeutic target in PDAC,and rationally designed mTOR inhibitor(mTORi)-based combination therapies are emerging[2].展开更多
基金the support of the European Research Council(ERC NoNaCat grant no.670986)the Federal Ministry of Education and Research(BMBF)the State of Mecklenburg-Vorpommern.
文摘The production of bulk organic chemicals has a strong impact on our daily life.In this review,an overview of important industrial processes using homogeneous catalysts is given.Using specific carbonylation and hydrogenation case studies,we want to show how basic research can contribute to the development of such processes and what challenges exist in this area of academic research.
基金FUNDING STATEMENT This work was supported by the Deutsche Forschungsgemeinschaft(DFG):SFB824 C9 to D.S.and G.S.SCHN 959/3-2 to G.S.+6 种基金SFB1321(Project-ID 329628492)P13 to G.S.SFB1321(Project-ID 329628492)P11 to D.S and M.S.R.SFB1321 S01 and S02 to G.S.,M.R.,D.S.,and R.RSCHN 959/6-1 to G.S.RE 3723/4-1 to M.R.,SFB1361(Project-ID ID 393547839)to O.H.KDFG KR2291-9-1/12-1/14-1 to O.H.K.,Wilhelm-Sander-Stiftung(2017.048.2 toG.S.and 2019.086.1 to G.S.and O.H.K.)Deutsche Krebshilfe(70113760 toG.S.,Max Eder Program 111273 to M.R.)and Brigitte und Dr.Konstanze Wegener-Stiftung(Projekt 65)to O.H.K.This research project/publication was funded by LMU Munich's Institutional Strategy LMU excellent within the framework of the German Excellence Initiative to M.S.R.
文摘Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)remains a significant health problem with an increase in the incidence and a five-year survival rate of only 10%[1].The Phosphoinositide 3-kinase-protein kinase-B-mechanistic target of rapamycin(PI3K-AKT-mTOR)pathway is a driver pathway in PDAC and an important therapeutic target[2].We[3]and others[4–6]have demonstrated that the mTOR kinase is a therapeutic target in PDAC,and rationally designed mTOR inhibitor(mTORi)-based combination therapies are emerging[2].
